Mariper (Perindopril Tert-Butylamine)

• Mariper (perindopril) is an ACE inhibitor used in cardiovascular disease management.
• Hypertension: lowers both systolic and diastolic blood pressure, thereby decreasing the long‑term risk of stroke, kidney damage and other hypertension‑related complications.
• Chronic heart failure: enhances cardiac output by reducing afterload, which can lead to symptomatic improvement, fewer hospital admissions, and better overall survival in patients with reduced ejection fraction.
• Post‑myocardial infarction: attenuates ventricular remodeling and reduces the incidence of recurrent myocardial infarction, heart failure progression, and cardiovascular mortality after an acute coronary event.

• Perindopril is a prodrug that is converted to perindoprilat, a potent inhibitor of the angiotensin‑converting enzyme (ACE). By blocking ACE, it prevents the conversion of angiotensin I to the vasoconstrictor angiotensin II and reduces degradation of bradykinin, resulting in vasodilation, decreased aldosterone secretion, and lowered systemic vascular resistance. The net effect is reduced blood pressure and decreased cardiac workload.

Perindopril may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

• Cough: dry, persistent cough due to increased bradykinin levels.
• Dizziness: especially upon standing, related to blood pressure reduction.
• Headache: mild to moderate intensity.
• Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue or airway, requiring immediate medical attention.
• Hyperkalemia: elevated blood potassium that can affect cardiac rhythm.
• Acute renal impairment: sudden decline in kidney function, particularly in patients with pre‑existing renal disease or volume depletion.

When prescribing perindopril, clinicians should consider several precautionary measures to ensure safe use.

• Renal function: assess baseline kidney function and monitor periodically, as ACE inhibitors can affect glomerular filtration.
• Electrolytes: check serum potassium and sodium levels, especially in patients receiving potassium‑sparing diuretics.
• Hypotension: initiate therapy at low dose and monitor for symptomatic low blood pressure, particularly in volume‑depleted individuals.
• Pregnancy: avoid use during the second and third trimesters due to risk of fetal toxicity; discontinue if pregnancy is confirmed.
• Drug interactions: review concomitant medications such as NSAIDs, diuretics, or other renin‑angiotensin system blockers that may amplify adverse effects.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Perindopril can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Combined ACE inhibitor or ARB therapy: may cause excessive hypotension and renal dysfunction.
• Potassium‑sparing diuretics or supplements: increase risk of hyperkalaemia.
• Aliskiren in diabetic patients: heightened risk of renal impairment, hypotension, and hyperkalaemia.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function.
• Diuretics: can potentiate initial blood pressure drop; monitor electrolytes.
• Lithium: ACE inhibition may raise lithium levels, increasing toxicity risk.